Therapeutic targeting of the PKA-p38MAPK-NFAT5-organic osmolytes pathway could be considered as a supportive treatment for DMD in conjunction with genetic therapy or as putative molecules to be investigated in experimental DMD studies. Here, NFAT5 is linked to Duchenne muscular dystrophy.